

Singaporean startup ImmunoScape raises \$14M to advance capabilities

19 April 2021 | News

Round is co-led by EDBI, Anzu Partners and UTEC, representing major biotech innovation centers across the U.S., Singapore and Japan



ImmunoScape, a Singapore headquartered biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, has announced it has completed a \$14 million fundraising round led by existing investors Anzu Partners, University of Tokyo Edge Capital Partners (UTEC) and new investor EDBI, an investment arm of the Economic Development Board of Singapore. The new round brings ImmunoScape's total funding in the past year to \$25 million.

ImmunoScape will use the funding to enlarge its Singapore-based team, further its expansion into the U.S., and scale up its newly announced San Diego laboratory.

The company will also be able to continue advancing the capabilities of its Deep Immunomics platform that enables the characterization of a patient's immunome at ultra-high resolution.

ImmunoScape will be working to increase its capacity for in-house R&D activities and to expand its partnerships with biopharma and leading academics in drug development efforts within immuno-oncology, infectious disease, and autoimmune disease.

ImmunoScape's Deep Immunomics platform integrates single-cell analysis technologies and cutting-edge bioinformatics for both drug discovery and high-dimensional immune profiling. For example, its TargetScape[®] technology can be used to detect rare antigen specific T-cells with frequencies as low as 1 in 100,000 CD8+ cells, and simultaneously provide comprehensive phenotypic information for these antigen specific T cells.